Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients
Surowiak, Pł.; Materna, V.; Kłak, K.; Spaczyński, M.; Dietel, M.; Kristiansen, G.; Lage, H.; Zabel, M.
Polish Journal of Pathology Official Journal of the Polish Society of Pathologists 56(2): 69-74
2005
ISSN/ISBN: 1233-9687 PMID: 16092668 Document Number: 588770
CD24 is a small membranous protein which may participate in invasion of tumor cells. Present study aimed at evaluation of prognostic significance linked to immunohistochemical demonstration of CD24 expression and the proliferation index, Ki67 expression in ovarian cancers. The immunohistochemical reactions with monoclonal CD24- and Ki67-specific antibodies were performed in paraffin sections originating from 30 patients with ovarian cancer treated using cisplatin and paclitaxel. Results of the reactions and analysis of the clinical course of the patients were subjected to statistical analysis. Cases with cytoplasmic-membranous expression of CD24 (CD24c-m) were found to exhibit significantly shorter overall survival time (P=0.0002) and progression-free period (P=0.0005). Cases with membranous expression of CD24 (CD24m) manifested a longer overall survival time (P=0.022). No relationship was disclosed between expression of Ki67 on the one hand and survival time and CD24 expression on the other. As documented using chi square test, expression of CD24c-m predisposed to relapses (P=0.012), progression (P=0.0362) and to death (P=0.0034). Deaths were encountered significantly less frequently in cases with CD24m expression (P=0.0465). The studies demonstrated that CD24c-m represented a strongly unfavorable prognostic indicator. The antigen represents an interesting target in the search for novel therapeutic methods. The more aggressive course of cases with CD24c-m expression was not linked to more intense proliferation of the tumor cells.